Summary Report of Expert Seminar on Clinical Use of Linaclotide

Abstract

Linaclotide is the first secretagogue approved for the treatment of irritable bowel syndrome with constipation in China. A group of experts in digestive diseases was convened to discuss the clinical use of linaclotide in China on June 26, 2021. Experts concluded at the seminar that the clinical efficacy of linaclotide should be comprehensively evaluated based on the improvement of constipation and abdominal symptoms; the clinicians should emphasize the importance to patient satisfaction; and the administration time, dose and duration of linaclotide treatment can be optimized according to the treatment response, lifestyle, severity of symptoms and drug sensitivity. In addition, the experts believed that communication with patients should be strengthened to help them to establish reasonable expectations to the efficacy and optimize the treatment regimen timely according to their feedback.